Highlights d Analyses of 184 immune features define kinetics of immune responses to SARS-CoV-2 d Circulating T FH 1 cells in acute COVID-19 correlate with antibodies d sIL-6R levels are elevated in severe COVID-19 but do not correlate with IL-6 d Elevated IL-6 and IL-18 correlate with immune cell hyperactivation
Highlights d Single-cell RNA-seq reveals two distinct B cell lineages d An alternative lineage contains CXCR3 + and atypical B cells d Alternative B cells are primed after primary vaccination and respond to boosters d Alternative B cells adopt a more atypical phenotype following repeated antigen exposure
To better understand primary and recall T cell responses during COVID-19, it is important to examine unmanipulated SARS-CoV-2-specific T cells. Using peptide-HLA tetramers for direct
ex vivo
analysis, we characterized CD8
+
T cells specific for SARS-CoV-2 epitopes in COVID-19 patients and unexposed individuals. Unlike CD8
+
T cells directed towards subdominant epitopes – B7/N
257
, A2/S
269
and A24/S
1208
– CD8
+
T cells specific for the immunodominant B7/N
105
epitope were detected at high frequency in pre-pandemic samples, and at increased frequency during acute COVID-19 and convalescence. SARS-CoV-2-specific CD8
+
T cells in pre-pandemic samples from children, adults and elderly individuals predominantly displayed a naïve phenotype, indicating a lack of previous cross-reactive exposures. T cell receptor (TCR) analyses revealed diverse TCRαβ repertoires and promiscuous αβ-TCR pairing within B7/N
105
+
CD8
+
T cells. Our study demonstrates high naive precursor frequency and TCRαβ diversity within immunodominant B7/N
105
-specific CD8
+
T cells, and provides insight into SARS-CoV-2-specific T cell origins and subsequent responses.
An improved understanding of human T cell-mediated immunity in COVID-19 is important for optimizing therapeutic and vaccine strategies. Experience with influenza shows that infection primes CD8+ T cell memory to peptides presented by common HLA types like HLA-A2, which enhances recovery and diminishes clinical severity upon reinfection. Stimulating peripheral blood mononuclear cells from COVID-19 convalescent patients with overlapping peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the clonal expansion of SARS-CoV-2−specific CD8+ and CD4+ T cells in vitro, with CD4+ T cells being robust. We identified two HLA-A*02:01-restricted SARS-CoV-2-specfic CD8+ T cell epitopes, A2/S269–277 and A2/Orf1ab3183–3191. Using peptide−HLA tetramer enrichment, direct ex vivo assessment of A2/S269+CD8+ and A2/Orf1ab3183+CD8+ populations indicated that A2/S269+CD8+ T cells were detected at comparable frequencies (∼1.3 × 10−5) in acute and convalescent HLA-A*02:01+ patients. These frequencies were higher than those found in uninfected HLA-A*02:01+ donors (∼2.5 × 10−6), but low when compared to frequencies for influenza-specific (A2/M158) and Epstein–Barr virus (EBV)-specific (A2/BMLF1280) (∼1.38 × 10−4) populations. Phenotyping A2/S269+CD8+ T cells from COVID-19 convalescents ex vivo showed that A2/S269+CD8+ T cells were predominantly negative for CD38, HLA-DR, PD-1, and CD71 activation markers, although the majority of total CD8+ T cells expressed granzymes and/or perforin. Furthermore, the bias toward naïve, stem cell memory and central memory A2/S269+CD8+ T cells rather than effector memory populations suggests that SARS-CoV-2 infection may be compromising CD8+ T cell activation. Priming with appropriate vaccines may thus be beneficial for optimizing CD8+ T cell immunity in COVID-19.
The hallmarks of COVID-19 are higher pathogenicity and mortality in the elderly compared to children. Examining baseline SARS-CoV-2 cross-reactive immunological responses, induced by circulating human coronaviruses (hCoVs), is needed to understand such divergent clinical outcomes. Here we show analysis of coronavirus antibody responses of pre-pandemic healthy children (n = 89), adults (n = 98), elderly (n = 57), and COVID-19 patients (n = 50) by systems serology. Moderate levels of cross-reactive, but non-neutralizing, SARS-CoV-2 antibodies are detected in pre-pandemic healthy individuals. SARS-CoV-2 antigen-specific Fcγ receptor binding accurately distinguishes COVID-19 patients from healthy individuals, suggesting that SARS-CoV-2 infection induces qualitative changes to antibody Fc, enhancing Fcγ receptor engagement. Higher cross-reactive SARS-CoV-2 IgA and IgG are observed in healthy elderly, while healthy children display elevated SARS-CoV-2 IgM, suggesting that children have fewer hCoV exposures, resulting in less-experienced but more polyreactive humoral immunity. Age-dependent analysis of COVID-19 patients, confirms elevated class-switched antibodies in elderly, while children have stronger Fc responses which we demonstrate are functionally different. These insights will inform COVID-19 vaccination strategies, improved serological diagnostics and therapeutics.
Humans
commonly have low level antibodies to poly(ethylene) glycol
(PEG) due to environmental exposure. Lipid nanoparticle (LNP) mRNA
vaccines for SARS-CoV-2 contain small amounts of PEG, but it is not
known whether PEG antibodies are enhanced by vaccination and what
their impact is on particle–immune cell interactions in human
blood. We studied plasma from 130 adults receiving either the BNT162b2
(Pfizer-BioNTech) or mRNA-1273 (Moderna) mRNA vaccines or no SARS-CoV-2
vaccine for PEG-specific antibodies. Anti-PEG IgG was commonly detected
prior to vaccination and was significantly boosted a mean of 13.1-fold
(range 1.0–70.9) following mRNA-1273 vaccination and a mean
of 1.78-fold (range 0.68–16.6) following BNT162b2 vaccination.
Anti-PEG IgM increased 68.5-fold (range 0.9–377.1) and 2.64-fold
(0.76–12.84) following mRNA-1273 and BNT162b2 vaccination,
respectively. The rise in PEG-specific antibodies following mRNA-1273
vaccination was associated with a significant increase in the association
of clinically relevant PEGylated LNPs with blood phagocytes ex vivo.
PEG antibodies did not impact the SARS-CoV-2 specific neutralizing
antibody response to vaccination. However, the elevated levels of
vaccine-induced anti-PEG antibodies correlated with increased systemic
reactogenicity following two doses of vaccination. We conclude that
PEG-specific antibodies can be boosted by LNP mRNA vaccination and
that the rise in PEG-specific antibodies is associated with systemic
reactogenicity and an increase of PEG particle–leukocyte association
in human blood. The longer-term clinical impact of the increase in
PEG-specific antibodies induced by lipid nanoparticle mRNA vaccines
should be monitored. It may be useful to identify suitable alternatives
to PEG for developing next-generation LNP vaccines to overcome PEG
immunogenicity in the future.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.